{"id":"satraplatin","rwe":[],"tags":[{"label":"satraplatin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01XA04","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["satraplatin","JM216","BMS 182751","BMY 45594"],"offLabel":[],"synonyms":["satraplatin","JM216","BMS 182751","BMY 45594"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"satraplatin","explanation":"Imagine your body's cells have a repair crew that fixes damaged DNA. Satraplatin blocks this repair crew, making it harder for cancer cells to fix their DNA and survive. This allows chemotherapy drugs to be more effective at killing cancer cells.","oneSentence":"Satraplatin works by inhibiting the enzyme DNA repair, which allows cancer-killing chemotherapy drugs to be more effective.","technicalDetail":"Satraplatin is a platinum-based drug that acts as a DNA crosslinking agent, inhibiting the DNA repair enzyme PARP and other mechanisms involved in DNA repair, leading to increased DNA damage and apoptosis in cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4703","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SATRAPLATIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SATRAPLATIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:35:35.001727","biosimilars":[],"competitors":[{"drugName":"cisplatin","drugSlug":"cisplatin","fdaApproval":"1978-12-19","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"carboplatin","drugSlug":"carboplatin","fdaApproval":"1989-03-03","patentExpiry":"Apr 1, 2045","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxaliplatin","drugSlug":"oxaliplatin","fdaApproval":"2002-08-09","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"satraplatin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cisplatin","brandName":"cisplatin","genericName":"cisplatin","approvalYear":"1978","relationship":"same-class"},{"drugId":"carboplatin","brandName":"carboplatin","genericName":"carboplatin","approvalYear":"1989","relationship":"same-class"},{"drugId":"oxaliplatin","brandName":"oxaliplatin","genericName":"oxaliplatin","approvalYear":"2002","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03258320","phase":"PHASE2,PHASE3","title":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":["Prostate Cancer Patients"],"enrollment":300,"completionDate":"2027-12"},{"nctId":"NCT00634647","phase":"PHASE2","title":"Satraplatin and Prednisone to Treat Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-19","conditions":["Prostate Cancer","Genetic Polymorphism"],"enrollment":24,"completionDate":"2012-05-01"},{"nctId":"NCT01259479","phase":"PHASE1","title":"Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12-03","conditions":["Solid Tumors","Brain Tumors","Brain Metastases"],"enrollment":9,"completionDate":"2015-05-29"},{"nctId":"NCT00499694","phase":"NA","title":"Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-10","conditions":["Prostate Cancer"],"enrollment":31,"completionDate":"2012-11"},{"nctId":"NCT01289067","phase":"PHASE2","title":"Utilizing A Genomic Sig for \"BRCAness\" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca","status":"COMPLETED","sponsor":"William K. Oh","startDate":"2010-12","conditions":["Prostate Cancer"],"enrollment":13,"completionDate":"2013-05"},{"nctId":"NCT00473720","phase":"PHASE1","title":"Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-05","conditions":["Advanced Cancers"],"enrollment":15,"completionDate":"2010-06"},{"nctId":"NCT00093132","phase":"PHASE1,PHASE2","title":"Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy","status":"TERMINATED","sponsor":"Agennix","startDate":"2004-08","conditions":["Carcinoma, Non-small Cell Lung","Lung Cancer"],"enrollment":20,"completionDate":"2009-02"},{"nctId":"NCT00450970","phase":"PHASE3","title":"Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)","status":"TERMINATED","sponsor":"Agennix","startDate":"2007-02","conditions":["Prostate Cancer"],"enrollment":344,"completionDate":"2009-12"},{"nctId":"NCT00370383","phase":"PHASE2","title":"A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Agennix","startDate":"2006-07","conditions":["Lung Cancer"],"enrollment":100,"completionDate":"2009-03"},{"nctId":"NCT00069745","phase":"PHASE3","title":"Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen","status":"COMPLETED","sponsor":"Agennix","startDate":"2003-09","conditions":["Prostate Cancer","Hormone Refractory Prostate Cancer"],"enrollment":0,"completionDate":"2007-03"},{"nctId":"NCT00313456","phase":"PHASE1","title":"A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel","status":"TERMINATED","sponsor":"Agennix","startDate":"2006-03","conditions":["Tumors","Prostate Cancer"],"enrollment":25,"completionDate":"2009-03"},{"nctId":"NCT00268970","phase":"PHASE2","title":"Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Agennix","startDate":"2005-12","conditions":["Non-small Cell Lung Cancer"],"enrollment":40,"completionDate":"2009-09"},{"nctId":"NCT00265655","phase":"PHASE2","title":"Satraplatin for Patients With Metastatic Breast Cancer (MBC)","status":"COMPLETED","sponsor":"Agennix","startDate":"2005-11","conditions":["Metastatic Breast Cancer"],"enrollment":40,"completionDate":"2008-02"},{"nctId":"NCT00125411","phase":"PHASE1","title":"Study of Satraplatin (JM-216) in Combination With Docetaxel","status":"TERMINATED","sponsor":"Agennix","startDate":"2007-03","conditions":["Tumors"],"enrollment":28,"completionDate":"2009-02"},{"nctId":"NCT00329329","phase":"PHASE1","title":"Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Agennix","startDate":"2006-05","conditions":["Malignancies"],"enrollment":24,"completionDate":"2009-02"},{"nctId":"NCT00480623","phase":"PHASE1","title":"A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence","status":"TERMINATED","sponsor":"Agennix","startDate":"2007-05","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2008-04"},{"nctId":"NCT01220284","phase":"PHASE1","title":"Satraplatin and Vinorelbine in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Southern Europe New Drug Organization","startDate":"2008-02","conditions":["Advanced Solid Tumors"],"enrollment":27,"completionDate":"2011-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"8D7B37T28G","CHEBI":"CHEBI:85609","INN_ID":"7780","RXNORM":"1733681","UMLSCUI":"C1142934","ChEMBL_ID":"CHEMBL3833367","KEGG_DRUG":"D05807","DRUGBANK_ID":"DB04996","PUBCHEM_CID":"6918220","SNOMEDCT_US":"428317007","MESH_SUPPLEMENTAL_RECORD_UI":"C081294"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XA04","allCodes":["L01XA04"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"SATRAPLATIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Satraplatin is a small molecule drug in the satraplatin class, originally developed by and currently owned by a pharmaceutical company. Its target and exact mechanism of action are unknown, but it is believed to work by inhibiting DNA repair mechanisms in cancer cells. Satraplatin has not been approved by the FDA for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to determine its safety and efficacy in treating various cancers. As a result, key safety considerations and potential side effects are currently unclear.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-12-31T00:00:00.000Z","mah":"Pharmion Ltd.","brand_name_local":"Orplatna","application_number":"EMEA/H/C/000888"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orplatna","application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}